Gilead Sciences (GILD) Misses Q2 EPS by 31c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $146.85 +1.82%
Revenue Growth %: -0.4%
Financial Fact:
Net loss attributable to noncontrolling interest: -5M
Today's EPS Names:
AEHR, VFS, CMTL, More
Revenue Growth %: -0.4%
Financial Fact:
Net loss attributable to noncontrolling interest: -5M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.34, $0.31 worse than the analyst estimate of $1.65. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.45 billion.
GUIDANCE:
Gilead Sciences sees FY2023 EPS of $6.45-$6.80, versus the consensus of $6.73. Gilead Sciences sees FY2023 revenue of $26.3-26.7 billion, versus the consensus of $26.663 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Profound Medical raises Q3 2026 revenue outlook above estimates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
